Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Napigen Inc. is currently addressing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner and is located in 1 distinct art unit. The company's current patent activity is highly concentrated, reflecting a singular focus within the patent office's administrative structure for its pending biotechnology innovations.
The busiest examiner for the portfolio is DEVEAU ROSEN, JASON, who is managing 1 busiest examiner pending action. This figure represents the total of 1 pending office actions for Napigen Inc. As a result, the company's immediate patent outcomes depend on the specific interactions with this 1 examiner in the Biotechnology & Pharmaceuticals field, rather than a broader group of examination officials.
The use of 1 distinct art unit indicates that the pending technology falls into a specific sub-category of biotechnology. With only 1 distinct examiner involved, the company does not need to manage multiple prosecution timelines or varying examiner styles. This streamlined environment allows for a focused approach to resolving the 1 pending office action through a single point of contact at the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEVEAU ROSEN, JASON | 1 | 80.1% | +16.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18716877 | PHOSPHITE DEHYDROGENASE AS A SELECTABLE MARKER FOR MITOCHONDRIAL TRANSFORMATION | DEVEAU ROSEN, JASON | 10d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18716877 | PHOSPHITE DEHYDROGENASE AS A SELECTABLE MARKER FOR MITOCHONDRIAL TRANSFORMATION | DEVEAU ROSEN, JASON | 10d overdue |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18716877 | PHOSPHITE DEHYDROGENASE AS A SELECTABLE MARKER FOR MITOCHONDRIAL TRANSFORMATION | DEVEAU ROSEN, JASON | 1662 | §103 | Final Rejection | 10d overdue | Pending | Jun 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial